UW performed almost all statistical analyses. Abidin, Ali Hussain, Natasha Ali and Syed Faisal Mahmood in Clinical and Applied Thrombosis/Hemostasis Abstract Background Instances of thrombosis with thrombocytopenia syndrome (TTS) have been reported following vaccination with AZD1222 or Ad26.COV2.S. This review targeted to explore the pathophysiology, epidemiology, analysis, management, and prognosis of TTS. Methods A systematic review was carried Rabbit polyclonal to COT.This gene was identified by its oncogenic transforming activity in cells.The encoded protein is a member of the serine/threonine protein kinase family.This kinase can activate both the MAP kinase and JNK kinase pathways. out to identify evidence on TTS till 4th September 2021. Case reports and series reporting patient-level data were included. Descriptive statistics were reported and compared across individuals with different sexes, age groups, vaccines, types of thrombosis, and results. Findings Sixty-two studies reporting 160 instances were included from 16 countries. Individuals were mainly females having a median age of 42.50 (22) years. AZD1222 was given to 140 individuals (875%). TTS onset occurred inside a median of 9 (4) days after Pramiracetam vaccination. Venous thrombosis was most common (61.0%). Most individuals developed cerebral venous sinus thrombosis (CVST; 66.3%). CVST was significantly more common in female vs male patients (p?=?0001) and in patients aged <45 years vs 45 years (p?=?0004). The mortality rate was 36.2%, and patients with suspected TTS, venous thrombosis, CVST, pulmonary embolism, or intraneural complications, patients not managed with non-heparin anticoagulants or IVIG, patients receiving platelet transfusions, and patients requiring intensive care unit admission, mechanical ventilation, or inpatient neurosurgery were more likely to expire than recover. Interpretation These findings help to understand the pathophysiology of TTS while also recommending diagnostic and management approaches to improve prognosis in patients. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Keywords: COVID-19 vaccines, ChAdOx1 COVID-19 vaccine, Ad26.COV2.S vaccine, thrombosis with thrombocytopenia syndrome, vaccine-induced immune thrombotic thrombocytopenia Introduction Having exerted widespread effects over all spheres of society, the coronavirus disease 2019 (COVID-19) pandemic has forced government and healthcare institutions to divert resources and develop methods to curtail it. Vaccines have been put under extreme emphasis as the primary method of halting transmission, with over one billion doses administered worldwide. Among these vaccines, the Oxford-AstraZeneca (AZD1222) and the Johnson & Johnson (Ad26.COV2.S) have recently been implicated in an extremely rare prothrombotic disorder comprising of thrombosis in uncommon sites with concurrent thrombocytopenia and development of anti-platelet factor Pramiracetam 4 (anti-PF4) antibodies.1,2 This disorder has been termed as thrombosis with thrombocytopenia syndrome (TTS). Owing to its atypical presentations, TTS can present as a diagnostic challenge for healthcare workers. The common manifestations range from routine constitutional changes to visual defects, severe headaches, leg and back pains, easy bruising, or petechiae. Unchecked, TTS may lead to cerebral hemorrhages and fatality.1,3 As reports of TTS came to light, administration of both vaccines was temporarily restricted, with Denmark and Norway permanently halting the AZD1222 vaccine. Similar to its rare occurrence, current evidence on TTS is also limited, existing in the form of case reports and series. Further hampering this issue, a large proportion of available data is centered around pharmacovigilance programs, such as Vaccine Adverse Event Reporting System (VAERS) and Medicines and Healthcare products Regulatory Agency (MHRA).4,5 While these systems are excellent at providing early warnings for pharmacological adverse events, their capacity to inform clinical decision-making is limited, owing to their reliance on non-standardized patient-reported outcomes. We conducted a systematic review of patient-level data with the Pramiracetam aim of summarizing the limited data available and explore the pathogenesis, epidemiology, clinical features, diagnoses, management, and prognoses in TTS patients. Methods The protocol of this review is registered with PROSPERO CRD42021252688, and this review has been reported in accordance with the Preferred Reporting Items for Pramiracetam Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Electronic Searches An exhaustive literature search was conducted on PubMed, Embase, CINAHL, Scopus, LILACS, Global Index Medicus, World Health Business (WHO) COVID-19 Database, Europe PMC, ScienceDirect, Preprints, medRxiv, Open Science Framework (OSF), and Research Square to identify all scientific literature available till 4th September 2021. No language restrictions were applied. The strategies employed for searching these databases are documented in Supplementary Appendix (p3-7). In addition, reference lists of all identified review articles and included studies were checked for additional references. To identify potentially relevant gray literature, reports and guidelines published by several hematological and pharmacovigilance businesses were hand searched (appendix p8). Selection Strategy Case reports and series providing patient-level data on TTS cases were included in this review. Patients with radiologically confirmed venous or arterial thrombosis and associated.